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Abstract
IMPORTANCE Fragility fracture is a major health issue because of the accompanying morbidity,
mortality, and financial cost. Despite the high cost to society and personal cost to affected
individuals, secondary fracture prevention is suboptimal in Norway, mainly because most patients
with osteoporotic fractures do not receive treatment with antiosteoporotic drugs after
fracture repair.
OBJECTIVES To improve secondary fracture prevention by introducing a standardized intervention
program and to investigate the effect of the program on the rate of subsequent fractures.
DESIGN, SETTING, AND PARTICIPANTS Trial protocol of the Norwegian Capture the Fracture
Initiative (NoFRACT), an ongoing, stepped wedge cluster randomized clinical trial in 7 hospitals in
Norway. The participating hospitals were cluster randomized to an intervention starting date: May 1,
2015; September 1, 2015; and January 1, 2016. Follow-up is through December 31, 2019. The outcome
data were merged from national registries of women and men 50 years and older with a recent
fragility fracture treated at 1 of the 7 hospitals.
DISCUSSION The NoFRACT trial is intended to enroll 82 000 patients (intervention period, 26 000
patients; control period, 56 000 patients), of whom 23 578 are currently enrolled by January 2018.
Interventions include a standardized program for identification, assessment, and treatment of
osteoporosis in patients with a fragility fracture that is led by a trained coordinating nurse. The
primary outcome is rate of subsequent fracture (per 10 000 person-years) based on national registry
data. Outcomes before (2008-2015; control period) and after (2015-2019; intervention period) the
intervention will be compared, and each hospital will act as its own control. Use of outcomes from
national registry data means that all patients are included in the analysis regardless of whether they
are exposed to the intervention (intention to treat). A sensitivity analysis with a transition window
will be performed to mitigate possible within-cluster contamination.
RESULTS Results are planned to be disseminated through publications in peer-reviewed journals
and presented at local, national, and international conferences.
CONCLUSIONS By introducing a standardized intervention program for assessment and treatment
of osteoporosis in patients with fragility fractures, we expect to document reduced rates of
subsequent fractures and fracture-related mortality.
(continued)
Key Points
Question What is the effect of a
fracture liaison service on the rate of
subsequent fractures?
Findings This trial protocol intends to
use merged outcome data from national
registers to include 82 000 women and
men 50 years and older with a fragility
fracture treated in 7 hospitals in Norway
in a stepped wedge cluster randomized
clinical trial introducing a standardized
intervention program. The use of
outcome data from national registers,
which include all patients in the analysis
regardless of whether they are exposed
to the intervention (intention to treat),
should ensure that outcomes are
assessed in a standardized way.
Meaning The design of this trial is
intended to overcome the ethical
challenges associated with traditional
randomized clinical trials and to
generate new knowledge on how to
improve the current standard of care.
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Introduction
Among women, a prior fracture doubles the risk of a future fracture and multiple fractures increase
the risk of future fractures up to 5 times.1 One-third of fractures occur within the first year and 75% of
subsequent fractures after a hip fracture occur within 5 years.2,3 Hip and vertebral fractures are
known to increase mortality, and new data suggest that other major osteoporotic fractures are also
associated with a reduction in life expectancy.4 Treatment of patients with fragility fractures should
therefore not only focus on the current fracture but also on preventing future fractures. Even though
treatment for osteoporosis is readily available and can reduce the risk of future fractures by 20% to
50%,5,6 the assessment and treatment for osteoporosis after a fragility fracture has been
suboptimal. Two Norwegian studies7,8 have demonstrated that only 15% of women and 4% of men
were treated with antiosteoporotic drugs after a hip fracture,7 and 11% of women and 3% of men
were treated with antiosteoporotic drugs the first year after a forearm fracture.8 These findings are
consistent with those of studies from other countries where less than 20% of patients with a fragility
fracture received treatment for osteoporosis.9,10
A fracture liaison services (FLS) model of care with a dedicated coordinator and a systematic
approach to identify, assess, and treat patients with a fragility fracture for osteoporosis has been
introduced in numerous places.11,12 The FLS programs have been shown to increase the referrals to
bone mineral density (BMD) measurements using dual-energy x-ray absorptiometry for screening of
osteoporosis.12 In a Swedish minimal FLS that was coordinated by medical secretaries, the proportion
of patients receiving dual-energy x-ray absorptiometry evaluation increased from 8% to 40% and
the treatment rate increased from 13% to 32%. Furthermore, individuals who received treatment had
a 51% lower risk of subsequent fractures compared with those who did not receive treatment.13
Few researchers have studied subsequent fracture rates and mortality as outcomes in studies
of the effect of FLS programs.13-20 In Australia, a 30% reduction in risk of any subsequent fracture
and a 40% reduction in risk of major subsequent fractures were shown.14 In the Netherlands, a
significant decrease in mortality of 33% was reported,15 and in England, a reduction around 20% was
found.16 However, a Swedish study showed no effect of FLS on subsequent fracture rates or
mortality, and an Australian study reported the effect of FLS on risk of subsequent fractures and no
effect on mortality rates.13,14 Studies of FLS with subsequent fracture rates and mortality as
outcomes are presented in Table 1. Although previous FLS studies are of great value, there has, to our
knowledge, been no randomized clinical trial on FLS with fracture rates and mortality as outcomes.
In a recent observational study,21 reduced mortality and subsequent fracture risk was shown in
individuals who were recommended anti-osteoporotic drugs as part of an FLS program. The authors
of that study proposed that traditional randomized clinical trials of FLS are unlikely to be performed
given the ethical challenges of randomizing some individuals to less-than-recommended care.
Moreover, the FLS program has not been evaluated on a public health scale, and more robust
evidence is therefore needed.11,22,23
When the Norwegian Capture the Fracture Initiative (NoFRACT) study was designed in 2014,
there was no systematic routine or national guideline for the identification and treatment of patients
with fragility fractures in Norway. Most patients were offered neither assessment nor treatment for
osteoporosis. This gap in care motivated a large-scale evaluation of the effect of introducing a
standardized secondary fracture prevention program on subsequent fracture rates and mortality in
Norway. The NoFRACT study is, to our knowledge, the first FLS study with a stepped wedge cluster
randomized clinical trial design, overcoming the ethical challenges of a traditional randomized clinical
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trial. The study may generate new knowledge and provide evidence on how to improve the current
standard of care.
The study has aimed to assess the effect of introducing an FLS standardized intervention
program for the treatment of osteoporosis in patients with a fragility fracture on subsequent fracture
rates (per 10 000 person-years). The study has also assessed the effect of introducing an FLS
standardized intervention program for treatment of osteoporosis in patients with a hip fracture on
all-cause mortality after hip fracture.
Methods
Study Setting
This trial protocol followed the Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) reporting guideline. For largely unknown reasons, Norway is among the countries with the
highest incidence rates of forearm and hip fractures worldwide.24-26 Each year, almost 10 000
Norwegians older than 50 years have a hip fracture, and the annual number of forearm fractures is
estimated to be approximately 15 000.25,27,28 Hip fractures account for almost 20% of fragility
fractures,29 implying a total of approximately 50 000 osteoporotic fractures annually in Norway.
Despite a decline in age-standardized hip fracture rates between 1999 and 2013, the total number of
hip fractures has increased owing to the aging population.26,30,31 The ongoing NoFRACT multicenter
study is being conducted in the orthopedic departments at the following 7 hospitals in Norway:
University Hospital of North Norway, Tromsø; St Olav’s University Hospital, Trondheim; Oslo University
Hospital, Oslo; Haukeland University Hospital, Bergen; Molde Hospital, Molde; Drammen Hospital,
Table 1. Studies of FLS With Rates of Subsequent Fracture and Mortality as Outcomes
Source Data Source
Intervention vs Control
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Abbreviations: FLS, fracture liaison service; HR, hazard ratio; ICD-9, International
Classification of Diseases, Ninth Revision; ICD-10, International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision; MTF, minimal trauma fracture;
NA, not applicable.
a Nonsignificant.
b The 95% CI was not provided in the original article.
c Because of the study design, data are shown for 1 group.
d Absolute rates because HRs and 95% CIs were not calculated.
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Drammen; and Bærum Hospital, Bærum. These hospitals represent both smaller and larger hospitals
and are geographically spread across Norway. The NoFRACT study has received approval from the
Regional Committee for Medical and Health Research Ethics, Region for South Eastern Norway, for the
merging of data from national registers and exemption from obtaining consent from the patients with
fractures. All data will be deidentified, and the code will be retained by the Norwegian Patient
Registry (NPR).
Trial Design, Randomization, and Recruitment
The hospitals were randomized to intervention starting date in a stepped wedge cluster randomized,
open cohort design.32,33 The design was chosen because FLS has been shown to be of more benefit
than harm, and this particular design is efficient for evaluating interventions that have previously
been found to be effective in individually randomized studies. We sought to evaluate the effect of the
intervention in a public health setting for implementation in clinical practice. In the design, the
intervention is introduced to each cluster at regular time intervals. Each hospital acts as its own
control, providing outcome data from before the intervention (2008-2015; control period) and after
the intervention (2015-2019; intervention period). Randomization by lottery was conducted 8 weeks
before the study start by an independent organization, the Norwegian Osteoporosis Association.
The intervention was introduced with 4-month intervals between the clusters, and the 7 hospitals
were divided into 3 sequences consisting of 2 to 3 clusters (hospitals) in each step. University
Hospital of North Norway, St Olav’s University Hospital, and Oslo University Hospital were scheduled
to start the intervention on May 1, 2015; Haukeland University Hospital and Molde Hospital on
September 1, 2015; and Drammen Hospital and Bærum Hospital on January 1, 2016 (Figure 1). The
recruitment phase has been ongoing from May 1, 2015, through December 31, 2018, with follow-up
planned throughout December 31, 2019. Different patients were included at each step but
subsequently followed up throughout the study period (open cohort design). The observation time
in the intervention period (2015-2019) will range from 12 to 56 months for each of the patients in the
study (unless an outcome or censoring takes place before the end of follow-up).
Eligibility Criteria
Women and men 50 years and older with a recently diagnosed low-energy fracture who were
admitted at 1 of the 7 hospitals were included, either while in the hospital or as outpatients within 6
weeks after the fracture. Patients with fractures of fingers, toes, skull, or face were ineligible. The
Figure 1. Norwegian Capture the Fracture Initiative (NoFRACT) Stepped Wedge Cluster Randomized Clinical Trial Design
St Olav’s University Hospital
Oslo University Hospital




































The 7 hospitals were randomized for the order of the starting dates and divided into 3
sequences. The intervention was introduced stepwise with 4-month intervals. The
intervention period started on May 1, 2015, and will continue through December 31,
2018, with follow-up through December 31, 2019. The University Hospital of North
Norway was scheduled to start on May 1, 2015, but was delayed for 5 months and started
on October 1, 2015.
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very fragile patients, who were not expected to live long enough for the intervention to take effect
as judged by the treating physician, will not receive the intervention. However, they will remain in the
statistical analyses (intention to treat).
Study Intervention
The intervention is a standardized program for identification, assessment, and treatment of
osteoporosis in patients with a recently diagnosed low-energy fracture (a fracture occurring after a
fall from standing height or less) and is based on the FLS model of care (Figure 2).
Identification
The coordinating nurse identifies the patients based on the hospital International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes and eligibility
criteria and provides information about the project either in person or in a letter sent to recently
discharged inpatients and outpatients.
Assessment
Blood samples are obtained from the patients with fractures within 6 weeks of the index fracture to
rule out common causes for secondary osteoporosis. The blood samples are assayed for serum levels
of 25-hydroxyvitamin D, calcium, parathyroid hormone, thyroid-stimulating hormone, albumin, and
Figure 2. Application of the Standardized Intervention Program in the Norwegian Capture the Fracture Initiative (NoFRACT) Trial
Advice on physical activity, healthy diet, and alcohol and tobacco consumption are given.
Calcium and vitamin D supplementation is recommended.
Information
Blood samples are assayed for serum 25-hydroxyvitamin D, calcium, PTH, TSH, albumin,
and eGFR. FRAX scorea and BMD T score are calculated if indicated.
Assessment
Patients 50 y and older with a fragility fracture are identified based on ICD-10 codes.
Information about NoFRACT is given either in person or by letter.
Identification
Treatment



























































while taking AOD or
with a BMD T score ≤–3.5
AOD indicates antiosteoporosis drugs; BMD, bone mineral density; eGFR, estimated
glomerular filtration rate; ICD-10, International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision; PTH, parathyroid hormone; and TSH, thyroid-
stimulating hormone.
a The Fracture Risk Assessment Tool (FRAX) is used to calculate the 10-year probability
of major osteoporotic fracture (score is given as a percentage; a higher percentage
indicates higher probability of fracture).
JAMA Network Open | Orthopedics Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture in Patients With Osteoporosis
JAMA Network Open. 2018;1(8):e185701. doi:10.1001/jamanetworkopen.2018.5701 December 7, 2018 5/13
Downloaded From:  by a Norwegian Institute of Public Health User  on 12/13/2018
creatinine. Kidney function is assessed using estimated glomerular filtration rate (eGFR).34 The BMD
is measured using dual-energy x-ray absorptiometry of both hips and spine, and BMD T score is
calculated. The 10-year probability of major osteoporotic fracture is calculated using the Fracture Risk
Assessment Tool (FRAX; score is given as a percentage, with a higher percentage indicating a higher
probability of fracture).35
Information
The coordinating nurse informs the patients on the importance of bone fragility and provides general
lifestyle advice on physical activity, healthy diet, and tobacco and alcohol consumption according to
national guidelines. All patients are recommended sufficient intake of calcium and vitamin D through
diet or supplementation (500-1000 mg of calcium and 800 IU of vitamin D daily). Patients are also
referred to fall prevention programs at the hospital or in primary care if the nurse finds this protocol
to be relevant.
Treatment
Antiosteoporotic drugs are offered to 4 groups of patients. In group 1, patients with hip fracture are
offered treatment regardless of BMD T score or FRAX score. The primary drug of choice for patients
with hip fracture is (1) intravenous zoledronic acid (5 mg per year) to evade compliance problems,
(2) oral alendronate (70 mg per week), or (3) subcutaneous denosumab (60 mg every 6 months).
In group 2, patients with vertebral fracture or 2 or more low-energy fractures are offered
treatment regardless of BMD T score or FRAX score with (1) oral alendronate (70 mg per week), (2)
intravenous zoledronic acid (5 mg per year), or (3) subcutaneous denosumab (60 mg every
6 months).
In group 3, patients with their first low-energy fracture are offered dual-energy x-ray
absorptiometry for assessment of BMD T score, FRAX score, or both. The same treatment as in group
2 is offered to those with a BMD T score greater than −3.5 and less than or equal to −1.5 or FRAX score
of major osteoporotic fracture of 20% or more.
In group 4, patients with a BMD T score of −3.5 or less or a subsequent low-energy fracture
while taking anti-osteoporotic drug treatment for more than 1 year are referred to an osteoporosis
specialist for consideration of bone anabolic treatment with teriparatide.
All patients are individually evaluated and treated according to comorbidities and kidney
function. Bisphosphonates (alendronate or zoledronic acid) are the drugs of choice unless the patient
had an eGFR of 35 mL/min or less; those patients are offered denosumab treatment unless they have
an eGFR of 20 mL/min or less or any other contraindication was present. Patients with elevated
serum levels of parathyroid hormone and calcium are referred to an endocrinologist, whereas
patients with smaller deviations in those levels are followed up for 2 to 4 weeks after treatment
initiation in primary care, as are patients with elevation of thyroid-stimulating hormone levels.
Length of treatment is dependent on the type of drug. For alendronate, a treatment break is
recommended after 5 years; for zoledronic acid, a treatment break is recommended after 3 years;
and for denosumab, no treatment break is recommended.
Adherence to the Protocol and to the Intervention
The coordinating nurses at the NoFRACT hospitals underwent training in FLS with a well-trained
nurse and physician to ensure standardization of the program. The University Hospital of North
Norway was scheduled to start on May 1, 2015, but was delayed for 5 months and started on October
1, 2015. All other hospitals initiated the intervention on the date as scheduled.
The patients who were prescribed treatment with antiosteoporotic drugs were offered
follow-up with the coordinating nurse. After 3 months, a phone consultation was performed to rule
out misunderstandings, answer questions, and take care of potential adverse events. The close
follow-up was conducted to improve the adherence to treatment. After 12 months, the patients were
again offered a phone consultation or an appointment with a nurse. Each patient and their general
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practitioner were advised concerning length of treatment, and the patient could be referred for a
reassessment after 2 to 3 years to decide further treatment.
Potential Harm From the Intervention
Exposure to the intervention is associated with minimal discomfort; however, blood samples are
obtained at baseline (start of the intervention), during which some patients may experience a slight
discomfort. Dual-energy x-ray absorptiometry is a painless imaging modality with a modest dose of
radiation.36 The most common adverse effects of antiosteoporotic drugs are muscle pains and
gastrointestinal symptoms, the latter of which are caused by oral bisphosphonates.37 Intravenous
treatment with zoledronic acid is associated with transient hypocalcemia and influenzalike
symptoms. In addition, bisphosphonates are rarely associated with risk of osteonecrosis of the jaw
and atypical femoral fracture.37 The patients were informed of potential adverse effects from the
treatment.
Study Outcomes
The primary study outcome is change in the rate of subsequent fracture (per 10 000 person-years)
for patients with the following ICD-10 codes: S22 (rib[s], sternum, and thoracic spine), S32 (lumbar
spine, pelvis), S42 (shoulder, upper arm), S52 (forearm), S62 (wrist, hand), S72 (femur), S82 (patella,
lower leg, and ankle), and S92 (foot). The secondary study outcome is all-cause mortality among
patients with the following ICD-10 codes: S72.0-S72.2 (hip fracture).
Sample Size Determination
Initially, the plan was to include 87 000 patients based on sample size calculations performed before
starting the trial (during 2008-2017) (ie, approximately 9600 patients each year). Local counting of
patients exposed to the NoFRACT intervention at the 7 Norwegian hospitals during 2015-2017
showed that approximately 7500 patients with fracture had been included annually. Because the
recruitment of patients had been somewhat lower than expected, a decision was made to continue
the recruitment for 1 additional year throughout 2018, with data obtained from registers throughout
2019 (to achieve at least 1 year of observation time for all patients). There are 4 months between the
steps in our design (3 steps per year) at the 7 hospitals; this design gives a mean cluster size of 357
patients (7500/[7 × 3] = 357). Because the baseline data from patients will be used for a total of 11
calendar years (2008-2018), a revised estimate of the number of patients who will be included is
82 467 (357 × 7 × 3 × 11 = 82 467; approximately 56 000 patients in the control period and 26 000
in the intervention period). Power calculations using the “steppedwedge” command in Stata, version
15 (StataCorp), show that we have 80% power to detect a relative risk of 0.73 for any type of
subsequent fracture in the intervention period vs control period. This figure assumes inclusion of
82 467 patients with fracture (any fracture type), intracluster correlation of 0.03, and cluster size of
357. The intracluster correlation was calculated as in a previous study.3 In these calculations, the
proportions of subsequent fracture in the intervention and control periods were estimated to be 6%
and 9%, respectively, after 1.5 years based on previous FLS studies.13,14,17 Estimates from the Swedish
study by Axelsson et al13 (after 0.9 years of follow-up: 6.6% in the treated group vs 8.8% in the
untreated group; relative risk, 0.75) were given the most weight because Sweden, similar to Norway,
has high fracture rates24; however, the incidence of fractures estimated in other relevant studies
were also considered.3,27,38,39
Regarding hip fracture risk among patients with a first fracture of any type, power calculations
give a relative risk of 0.52 in the intervention vs control periods, assuming 80% power, inclusion of
82 467 patients with fractures, proportions of patients with a subsequent hip fracture of 3.0% in the
control period and 1.6% in the intervention period, an intracluster correlation of 0.03, and a cluster
size of 357.3
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Data Sources and Collection
Outcome, time at risk, and potential confounding factors have been obtained since January 1, 2008,
and will continue to be collected through December 31, 2019, from the following national registries:
the NPR, National Population Register, Statistics Norway, and Norway Control and Reimbursement of
Healthcare Claims (KUHR) (Table 2). The NPR provides data on patients with fractures treated at
Norwegian hospitals. Fracture diagnoses other than hip fracture (which is always treated in hospitals)
is also complemented by the KUHR database, which comprises fractures treated by primary care
physicians and emergency units in rural and semirural areas.
Validity
The use of registry data are highly dependent on the quality of the registries. The accuracy of hip
fracture diagnosis in the NPR has been evaluated and found to be 93.5%.40 A study of the
distribution and degree of overlap of fracture diagnoses in the NPR and KUHR will be performed.
Ahead of our main analysis, the accuracy of the diagnosis of forearm fracture will also be evaluated in
a separate validation study that includes fractures from hospitals (registered in the NPR) and from
the primary health care service (registered in the KUHR).
Data Management
All data will be deidentified by replacing the personal identification number with a project-specific
identification number for each individual. The code (personal identification vs project-specific
identification) will be retained by the NPR. The data will be securely stored at a protected platform
for research at the University of Oslo, Services for Sensitive Data, which meets all Norwegian law
requirements. Data will be available only to collaborators with the approval by the Regional
Committee for Medical and Health Research Ethics, Region South Eastern Norway. All data
management (eg, quality control and linking of data sources) will be performed within the Services
for Sensitive Data.
Data Analysis Plan
Outcome data from the control period and intervention period will be compared. The date of the
index fracture (first fracture in the trial period) determines whether a patient’s data will be included
in the control or intervention period. The study will use time-to-event analysis, in which time at risk of
subsequent fractures will be calculated based on first fracture dates (hospitalization dates or primary
health care treatment dates), dates of migration or event occurrence (death from the National
Population Register or subsequent fracture from the NPR), or the end of the study (December 31,
2019). Using calendar time as the scale will allow observation of secular changes in subsequent
fracture risk over time, and if necessary, differences in secular trends between hospitals will be
considered by including an interaction term between cluster and time. Clustering by hospital will be
included as random effects in mixed models to estimate incidence rate ratios with 95% CIs. A uniform
correlation structure is assumed,41 with no decay in the cluster autocorrelation. All patients treated
for relevant fractures and residing in a municipality belonging to 1 of the 7 hospitals after initiation of
Table 2. National Registries Used for Outcome Assessment in the Norwegian Capture the Fracture Initiative
(NoFRACT) Study
Registry Variable Type of Fractures
Norwegian Patient Registry Sex, birth year, hospital, hospitalization dates,
municipality of residence, treatment level, surgical
procedure codes, and Charlson comorbidity index
Fractures treated in
hospitals
National Population Register Dates of migration and death, marital status, and
country of birth
All fractures




ICPC-2 diagnosis codes L72-L76, including subgroup Fractures treated in
primary care Abbreviation: ICCP-2, International Classification of
Primary Care, 2nd ed.
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the intervention will be allocated to the intervention group irrespective of exposure to the
intervention (intention to treat). Because risk of subsequent fracture varies by follow-up time and
fracture type,3,39 additional analyses will be performed in which the same maximum follow-up time
(1 year) after the index fracture will be used for patients in the control period.
The need for a transition period (period for the intervention to be established) to minimize
within-cluster contamination will be explored in sensitivity analyses. The pattern of missing data will
be examined, and if necessary, multiple imputation will be performed based on the collected
exposure data, covariates, outcome, and intracluster correlation. Analyses will be stratified by sex,
and subsequent fracture rates and mortality rates in women and men will be compared. The analyses
will be adjusted for potential confounders, such as age, education, and comorbidity (Charlson
index score).
Trial Status
At the beginning of January 2018, there were 23 578 patients enrolled in the intervention period of
the NoFRACT study of the approximately 26 000 patients planned.
Patient and Public Involvement
The development of NoFRACT was motivated by previous studies that showed undertreatment of
osteoporosis in patients with fragility fractures.7-10 Patients were not involved in the initial
development of the study design, conduct, and recruitment. However, 2 patients with a previous
fracture who have been receiving antiosteoporotic drugs have been involved in the later stages of the
study and contributed to the development of new research questions. The patients were recruited
through the NoFRACT network and were interviewed regarding preferences and experiences; they
also commented on the trial protocol. Patients’ priorities, experience, and preferences have also
been discussed in public meetings.
Dissemination Plan
The dissemination plan includes publication of positive, negative, and inconclusive results in peer-
reviewed Norwegian and international scientific journals. Primary and secondary outcomes will be
presented in separate papers. Authorship for the scientific papers will be settled according to the
Vancouver protocol and the International Committee of Medical Journal Editors recommendations.
The results from the study will be presented at national and international academic meetings. The
protocol and journal publications will be made available to the public; however, because of strict
protection of privacy under Norwegian law, individual-level data sets can only be shared if approved
by the Regional Committee for Medical and Health Research Ethics.
The results from the study will be disseminated to the public through newspapers, television,
public meetings, and social media in collaboration with 2 patient advisors. To reach the patients more
directly, the results will be communicated to treating physicians and hospital staff and through
patient organization. Implementation of research results into clinical practice is important. It is
therefore necessary to communicate research results and clinical treatment strategies to decision
makers to ensure that best clinical practice is implemented and made equally available for the
patients in Norway and worldwide.
Conclusions
By introducing a standardized intervention program for assessment and treatment of osteoporosis
in patients with fragility fractures, we expect to document reduced rates of subsequent fractures and
fracture-related mortality.
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